Introduction. 
Introduction
Carotid artery angioplasty with stenting (CAS) is increasingly playing a role as alternative for surgical endarterectomy (CEA) in high risk patients, and also in those patients who present with other, non-stenotic lesions of the carotid arteries [1] [2] [3] [4] . Most of published papers on CAS deal with distal protection systems (DPS) [5] [6] [7] [8] [9] . Still, it is believed that proximal protection systems (PPS) in terms of their safety and efficacy have potential advantage over distal ones, yet evidence of such superiority remains to be documented [10] [11] [12] [13] .
This post hoc survey, with 30-day follow-up, was aimed at the assessment of safety and efficacy of CAS with the use of PPS for the treatment of internal carotid artery (ICA) stenosis and at identification of risk factors associated with this procedure.
Material and methods
We analysed results of the treatment with the use of PPS in 94 consecutive patients (34 women and 60 men) who were managed by our team at departments of vascular surgery from March 2011 to December 2015. Table 1 , and comparison between asymptomatic and symptomatic patients regarding these risk factors is presented in Table 2 . Localisation of the lesions managed with stent implantation is given in Table 3 .
Flow Reversal System (Gore & Associates, Inc., Flagstaff, AZ, USA). The first system protects the brain against embolisation thanks to stopped flow in the ICA, which occurs after the balloons of this system are expanded in the common and external carotid arteries (Fig. 1A) . In the case of the Gore Flow system, there is a flow reversal in the ICA, which results from temporary shunting from the ICA to the femoral vein through catheters and filter of this device (Fig. 1B) . Mean time of closure of the common carotid artery was 422 s (± 178 s); the shortest closure time was 150 s. Characteristics of the types of PPS, stents utilised in our patients and presence of embolic material secured by protection systems are given in Table 4 . Standard preprocedural management of patients comprised multidisciplinary assessment, including neurological, vascular and cardiologic consultations. Potential risks and benefits associated with the planned procedure were discussed with the patients, and all patients gave their written informed consent. Neurological assessment was performed at least before the procedure and on the first postprocedural day. Sonographic follow-up of the treated arteries was performed on the day of procedure, and then after 1 and 6 months.
All patients completed the 30-day follow-up, which was primarily aimed at the assessment of safety of these endovascular procedures. Patients were advised to report any neurological events that occurred during this period. Neurological symptoms were categorized Right vertebral artery 1 1 Figure 1A . Scheme of Mo.Ma system -blockage flow in ICA during inflation of balloon in CCA and ECA; B. Scheme of Gore Flow Reversal System -there is a flow reversal in the ICA, which results from temporary shunting from the ICA to the femoral vein through catheters and filter of this device during inflation of balloon in ECA and CCA. CCA -common carotid artery; ECA -external carotid artery; ICA -internal carotid artery
Inclusion criteria for endovascular angioplasty with stent implantation comprised: more than 65% stenosis of the ICA in symptomatic patients and more than 80% stenosis of the ICA in asymptomatic patients. Main indication for the use of PSP instead of another type of protection included: presence of unstable symptomatic lesions, critically narrowed ICA, tortuosity of the artery, presence of thrombi in the lesion, technical problems with the use of a DPS.
Exclusion criteria for stenting procedure comprised: highly calcified lesions, no adequate vascular access, contraindications for antiplatelet therapy and a lack of patient's consent. Symptomatic patients were managed at least 5 days after neurologic event, preferentially on the 7 th -10 th day, depending on the findings of MRI of the brain and appearance of cerebral lesions revealed by this test; this was in line with recommendations coming from published studies [10, 12] .
Two types of PPS were utilised: the Mo.Ma (Medtronic, Minneapolis, MN, USA) and the Gore
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as follows: transient ischaemic attack, which was defined as an acute neurological deficit resulting from focal temporary cerebral or retinal ischaemia that lasted less than 24 hours; stroke, which was defined as a new cerebrovascular event of ischaemic or haemorrhagic aetiology resulting in cerebral infarction and neurological deficit. Strokes were further classified as: minor -with neurological deficits lasting less than 30 days, or lasting longer than 30 days but presenting with small deficit (National Institute of Health Stroke Scale up to 4 points); major -with neurological deficits lasting longer than 30 days; and fatal -a stroke (ischaemic or haemorrhagic) resulting in death. The primary endpoint was the proportion of patients who had stroke or stroke-related death. We included all types of strokes, both ipsi-and contralateral, as well as minor, major and fatal strokes.
The secondary endpoint was the proportion of patients who had myocardial infarction (both STEMI and non-STEMI events) or a death that was not caused by stroke. In addition to demographic and clinical data of the patients, we analysed angiographic characteristics, such as presence of coexisting lesions in other arteries supplying the brain, including intracranial stenoses. Also, we assessed endovascular technique used (type of protection, type of stent, duration of the procedure, duration of occlusion of an artery, etc.).
Statistical analysis
Continuous variables were expressed as means ± standard deviation; categorical variables were expressed as percentages. Analysis of normality was performed with the Kolmogorov-Smirnov test. Comparison of categorical variables between the groups was performed using the chi-square test. Comparisons of continuous variables between the two groups were performed using the independent sample t-test. Multivariate, stepwise backward conditional logistic regression analysis was used to determine independent predictors of successful intervention. All significant parameters in the univariate analysis were selected in the multivariate model. The significance of the two-tailed p was set at p < 0.05. Statistical analysis was performed using the SPSS software (Statistical Package for the Social Sciences (version 23.0, SPSS Inc., Chicago, IL, USA).
Results
Complications associated with the treatment are presented in Table 5 . There was neither a fatality nor a stroke during 30-day follow-up. Transient ischaemic During or after the procedure 3 asymptomatic (6.4%) and 2 symptomatic patients (4.0%) developed hypotension, which required an intravenous administration of dopamine, yet did not result in further clinical sequelae. Logistic multivariate analysis revealed several risk factors predisposing for peri-and postprocedural neurological complications, namely: TIA or intolerance of the protection system. These comprised: tortuosity of the managed artery, presence of long lesions in the internal carotid arteries, a history of chronic obstructive pulmonary disease or myocardial infarction. Details are given in Table 6 .
Discussion
Incidence of major adverse events in our material (0%) was much lower than recommended in the guidelines (3% for asymptomatic and 6% for symptomatic patients). Still, there are some limitations of our study. Firstly, it was a retrospective analysis and patients were not randomly allocated into PPS or DPS arms, thus a potential selection bias could occur. The same applies to the selection of stents, which were tailored according to the characteristics and anatomy of lesions. Also, this survey analysed adverse events during a 30-day follow-up, when perhaps a longer observation will be justified.
In our patients neurological adverse events (only: TIA and intolerance of protection system, since there were no strokes) were associated with several risk factors: tortuosity of the managed artery, long lesions in the ICA, history of chronic obstructive pulmonary disease and history of myocardial infarction. Other researchers found that complications were associated with bilateral carotid disease, long lesions, advanced patient's age and a history of myocardial infarction [10, 11, [13] [14] [15] [16] . Data revealed by large-scale registries on endovascular carotid interventions suggest that because of a risk of cerebral embolisation, the use of protection system during CAS is warranted [10, 11, 17, 18] . Indeed, in our patients very often there was quite a lot of embolic material filtered by protection system (Table 4) .
For the time being CAS procedures are primarily performed with the use of a (DPS) [5] [6] [7] [8] [9] . Prevalence of ischaemic cerebral events during 30-day follow-up reported by randomised trials, with different types of DSP utilised, was at the level of 4% in asymptomatic patients, and even as high as 10% in symptomatic individuals [5] [6] [7] [8] [9] . By contrast, open-label studies when also a proximal protection has been applied (such a system was used in approximately 30% of procedures) reported much lower rates of adverse events: 0.9-2.4% of death or stroke [10] [11] [12] [13] . There is a growing body of evidence supporting the use of PPS during CAS. Regarding the Mo.Ma system, there are some already published studies [12, 19, 20] . In the randomized multicentre ARMOUR study, which evaluated a group of 222 patients (15% of them were symptomatic, 29% were older than 80 years; occlusion or stenosis of the contralateral artery constituted an exclusion criterion for the use of PPS) the composite complication rate (comprising: stroke, death and myocardial infarction) was 2.7%, and stroke rate during 30 days was 0.9% [12] . In the study published by Stabile et al. the Mo.Ma system was used in 1,300 patients. The composite complication rate (comprising: stroke and death) at 30-day follow-up was 1.4% (3% in symptomatic patients and 0.9% in asymptomatic ones). It was not increased in elderly patients. Low operator experience (less than 100 procedures performed) was associated with a higher risk of adverse events [19] . In 2014 Khripun et al. published the results of an open-label study with the use of the Mo.Ma system. Incidence of complications during 30-day follow-up in this survey was 0.6% [20] .
Efficacy and safety of the Gore Flow Reversal System have been evaluated in the multicentre prospective, nonrandomized EMPiRE study [21] . In this study 245 patients have been studied, including 30% symptomatic and 16% older than 80 years. In this study contralateral stenosis or occlusion was not an exclusion criterion (actually, 10.5% of patients enrolled presented with Composite complication rate comprising only stroke and death was 2.9% (still, not a single patient in this study developed major stroke). The death/stroke rates in this study in the symptomatic, asymptomatic, and patients older than 80 years were 2.6%, 3%, and 2.6%, respectively [21] . Another study on the use of the Gore Flow Reversal System, which was published in 2012 by Nikas et al., revealed complication rate (comprising: stroke, death and myocardial infarction) at the level of 1.6% [22] . Similarly, clinical benefit associated with the use of a PPS has been demonstrated by cerebral diffusion MR studies. Bijuklic et al., who compared distal and proximal protection systems studying postprocedural cerebral lesions by means of diffusion MR imaging, found that there were significantly fewer new lesions (45.2% vs. 87.1%; p = 0.001) if the PPS were used [23] . Montoresi et al. [24] demonstrated that there were fewer periprocedural embolic events with the use of the Mo.Ma system if compared to a DPS: the FilterWire. Meta-analysis by Bersin et al. [25] , which was published in 2012 and discussed results of CAS with the use of PPS in 2397 patients, reported 1.71% stroke rate during 30-day follow-up and 2.6% incidence of stroke, death or myocardial infarction. In this meta-analysis diabetes mellitus and advanced patient's age were found to be associated with increased risk of adverse events.
All the above-citied data are in line with our results. There were neither fatalities nor strokes in our patients, and the only major adverse events comprised two TIAs that completely resolved within few hours, without further neurological sequelae. Although an introduction of PPS into the ICA can be technically challenging and there were many patients with contralateral carotid disease (about 40% of our patients presented with significant, at least 70%, stenosis of contralateral ICA, and about 5% of patients had completely occluded contralateral artery), only 5.1% of patients developed neurological symptoms after introduction of PPS and there were no clinical consequences related to this intolerance. By contrast, in the AROMOUR study, which did not enrol patients with significant contralateral carotid lesions, there was an intolerance of protection system in 13.8% of patients and 0.9% stroke rate [12] . Low incidence of neurological adverse events associated with the use of PPS by our team can partially be explained by some modifications of endovascular technique used. In each patient we tried to postpone the closure of the common carotid artery until the guidewire and stent were introduced into the distal part of the system. In selected cases (there were 2 such patients) we utilised both proximal and distal protections. Such a dual protection has already been shown to be safe and effective [22, 26] . Also, we applied lesion-tailored stents: preferentially closed-cell stents, but in selected patients who presented with tortuous arteries we implanted stents with an open-cell design (such as the Precise stent/Cordis, Fremont, CA, USA). Although we did not observe different clinical outcomes in patients managed with closed-and open-cell stents, other researchers revealed better results after implantation of closed-cell stents [27] . Still, for technical reasons, such stents cannot be used in every case. Recently, a new generation of carotid stents has been marketed; these stents combine small area of the cells with flexibility characteristic for open-cell devices. Perhaps, such stents, which appear to be an interesting alternative for currently utilised ones, will further improve results of carotid stenting [27, 28] .
Whilst our study is not definitive and therefore cannot guide the treatment, nonetheless we have found that in patients presenting with tortuosity of the managed artery, presence of long lesions in the internal carotid arteries, a history of chronic obstructive pulmonary disease or myocardial infarction, periprocedural adverse events were more likely that in patients without these risk factors. Thus, perhaps in individuals presenting with these comorbidities an alternative treatment modality should be considered, either surgical endarterectomy, carotid stenting with the use of distal protection, or pharmacological treatment.
Conclusions
We can conclude that CAS with the use of a PPS is a relatively safe endovascular procedure, with a potential benefit over DPS. We suggest that proximal protection devices should be used whenever technically feasible, still in patients presenting with risk factors of periprocedural adverse event, such as tortuosity of the managed artery, presence of long lesions in the internal carotid arteries, a history of chronic obstructive pulmonary disease or myocardial infarction, an alternative treatment modality should be considered. Future strategy treatment for carotid artery stenosis should be based on an individual approach.
